The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten

CombinatoRx (NASDAQ:CRXX)
Cash on hand: $26.5 million
Related Xconomy coverage:
“Former CEO Alexis Borisy Voices Mixed Feelings on CombinatoRx Saga”
“CombinatoRx Judgment Day Coming Soon, Arthritis Drug Results on the Way”
“CombinatoRx To Combine With Neuromed”

Cubist Pharmaceuticals (NASDAQ: [[ticker:CBST]])
Cash on hand: $474.4 million
Related Xconomy coverage:
“Alnylam, Cubist Will Cooperate on RNAi Drug for Lung Infections”
“Cubist Agrees to Promote AstraZeneca Antibiotic”

Curis (NASDAQ: [[ticker:CRIS]])
Cash on hand: $26.8 million
Related Xconomy coverage:
“Curis Gets $3M from Genentech for Ovarian Cancer Trial Initiation”

Dyax (NASDAQ: [[ticker:DYAX]])
Cash on hand: $53.1 million
Related Xconomy coverage:
“Dyax Hit With FDA Drug Delay”
“Dyax Lands Deal to Raise $50M”
“FDA Committee Votes in Favor of Dyax Lead Drug for Rare Blood Disease”

Genzyme (NASDAQ: [[ticker:GENZ]])
Cash on hand: $1.05 billion
Related Xconomy coverage:
“Genzyme Says Supplies of Two Enzyme Drugs Will Be Even Lower Than Previously Predicted”
“Genzyme’s Woes Piling Up as FDA Panel Says Data on Leukemia Drug Are Lacking”
“Genzyme Offers Glimpse at Growth Engine, New Drugs for High Cholesterol, Gaucher’s”
“Genzyme Halts Production at Allston Drug Plant After Virus Appears”
“Genzyme Reaching for a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs”

GTC Biotherapeutics (NASDAQ: [[ticker:GTCB]])
Cash on hand: $4.7 million
Related Xconomy coverage:
“FDA Approves First Drug Made From Bioengineered Goats”
“GTC Biotherapeutics Racing Against Time To Prove The Worth of Pharming, Thinks It Has the Edge”

Haemonetics (NYSE: [[ticker:HAE]])
Cash on hand: $173.8 million

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button. For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. *Price is subject to change without notice

Harvard Bioscience (NASDAQ: [[ticker:HBIO]])
Cash on hand: $16.8 million

Helicos Biosciences (NASDAQ: [[ticker:HLCS]])
Cash on hand: $8.4 million
Related Xconomy coverage:
“Helicos Biosciences, Running Low on Cash, Snaps Up $10M Lifeline”
“With New Machine, Helicos Brings Personal Genome Sequencing a Step Closer”
“Helicos Cuts 30 Percent of Workforce”
“Helicos Shuffles CEOs, Names Lowy to Top Job”

Hologic (NASDAQ: [[ticker:HOLX]])
Cash on hand: $243.7 million
Related Xconomy coverage:
“Third Wave Means Extra Power for Hologic”

Idenix Pharmaceuticals (NASDAQ: [[ticker:IDIX]])
Cash on hand: $51.7 million
Related Xconomy coverage:
“Idenix Inks HIV Drug Deal With GSK Worth Up To $450M”

Idera Pharmaceuticals (NASDAQ: [[ticker:IDRA]])
Cash on hand: $50.5 million
Related Xconomy coverage:
“Idera and Merck Extend R&D Deal”
“Idera Pharmaceuticals Inks Potential $400 Million Deal With Germany’s Merck”

ImmunoGen (NASDAQ: [[ticker:IMGN]])
Cash on hand: $71.1 million
Related Xconomy coverage:
“Souped Up Herceptin Aims to Validate Immunogen’s Long Sought Dream Cancer Drug”
“ASCO Weekend Highlights, Immunogen, Antigenics, Aveo Show Off Cancer Drug Findings”

Infinity Pharmaceuticals (NASDAQ: [[ticker:INFI]])
Cash on hand: $150.4 million
Related Xconomy coverage:
“Infinity Sees Comeback Potential for Cancer Drug That Failed”
“Infinity Pharma Lead Cancer Drug Trial Ends in Failure”
“Infinity Snags $75 Million Through Alliance With Purdue Pharma and Mundipharma“